Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes

摘要

Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.BackgroundDiabetic nephropathy is associated with increased albuminuria and accmulation of extracellular matrix proteins within the kidney. Clinical studies have shown some beneficial effects of calcium channel blockers (CCB) on diabetic nephropathy, even though they are generally considered to be less renoprotective than agents that interrupt the renin angiotensin system. However, effects of CCBs on renal injury, and in particular, expression of extracellular matrix proteins in a model of normotensive diabetic nephropathy, are poorly characterized.